Timeline
More in Healthcare
GSK drops camlipixant after mixed phase III cough trial results
GSK will halt further development of camlipixant for refractory chronic cough after one of two pivotal trials failed to hit its primary goal.
Search for companies, sectors, market news and more
Navigate
Browse by Sector
Market reports
Daily reports
Sector reports
Energy & Resources
Financials
Technology
Healthcare
Topics
Top Stocks
Industrials
Consumer
Top Stocks